Oncopharmpod
Elderly AML & Larotrectinib
- Author: Vários
- Narrator: Vários
- Publisher: Podcast
- Duration: 0:26:50
- More information
Informações:
Synopsis
The often encountered, seldom studied Elderly AML demographic is discussed in light of recent FDA approvals for glasdegib (new drug) and venetoclax (new indication). Then, (17:30) we discuss the 2nd drug "tissue agnostic" FDA approval by delving into NTRK-fusion-gene tumors and larotrectinib.
